Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase

Antiviral Therapy

Volumn 3, Issue 3, 1998, Pages 177-182

  Salomon, Horacio ^a,b   Montaner, Julio S G ^c   Belmonte, Antonietta ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CODON; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS MUTATION;

EID: 17344365671     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Larder BA, Darby G & Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-1734.
2. Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao XJ, Fanning M, Montaner JS, O'Shaughnessy M, Gelmon K, Tsoukas C, et al. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine (AZT) therapy. AIDS 1989; 3:411-415.
3. Land S, Treloar G, McPhee D, Birch C, Doherty R, Cooper D & Gust I. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. Journal of Infectious Diseases 1990; 161:326-329.
4. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM & Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrobial Agents and Chemotherapy 1995; 39:1704-1710.
5. Larder BA, Coates KE & Kemp SD. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. Journal of Virology 1991; 65:5232-5236.
6. Gao Q, Gu Z, Parniak MA, Li X & Wainberg MA. In vitro selection of variants of the human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. Journal of Virology 1992; 66:12-19.
7. Larder BA & Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246:1155-1157.
8. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp P, Kemp SD & Larder BA. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
9. Gu Z, Gao Q, Li X, Parniak MA & Wainberg MA. A novel mutation in the HIV-1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'dideoxycytidine. Journal of Virology 1992; 66:7128-7135.
10. Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J & Wainberg MA. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrobial Agents and Chemotherapy 1994; 38:275-281.
11. Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ & Dubin DT. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2'-3'-dideoxycytidine. Antimicrobial Agents and Chemotherapy 1992; 36:153-157.
12. Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS & D'Aquila RT. Resistance to 2'-3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodefiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 1994; 38:282-287.
13. Schinazi RF, Lloyed RM Jr, Nguyen M-H, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ & Mellors JW. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents and Chemotherapy 1993; 37:875-881.
14. Tisdale M, Kemp SD, Parry NR & Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1993; 90:5653-5656.
15. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C & Wainberg MA. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrobial Agents and Chemotherapy 1993; 37:1390-1392.